PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-100.00%
Revenue decline while TRVN shows 124.69% growth. Joel Greenblatt would examine competitive position erosion.
8.54%
Cost increase while TRVN reduces costs. John Neff would investigate competitive disadvantage.
-83.05%
Gross profit decline while TRVN shows 90.22% growth. Joel Greenblatt would examine competitive position.
No Data
No Data available this quarter, please select a different quarter.
-18.94%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
28.45%
G&A change of 28.45% while TRVN maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.25%
Operating expenses reduction while TRVN shows 13.68% growth. Joel Greenblatt would examine advantage.
-7.93%
Both companies reducing total costs. Martin Whitman would check industry trends.
-100.00%
Interest expense reduction while TRVN shows 0.00% growth. Joel Greenblatt would examine advantage.
8.54%
D&A growth while TRVN reduces D&A. John Neff would investigate differences.
7.52%
EBITDA growth below 50% of TRVN's 69.35%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
7.21%
Operating income growth exceeding 1.5x TRVN's 2.65%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-9.03%
Other expenses reduction while TRVN shows 134.57% growth. Joel Greenblatt would examine advantage.
7.01%
Pre-tax income growth below 50% of TRVN's 53.49%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
-68.42%
Tax expense reduction while TRVN shows 148.47% growth. Joel Greenblatt would examine advantage.
7.01%
Net income growth below 50% of TRVN's 53.49%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
8.82%
EPS growth below 50% of TRVN's 65.85%. Michael Burry would check for structural issues.
8.82%
Diluted EPS growth below 50% of TRVN's 65.85%. Michael Burry would check for structural issues.
0.91%
Share count reduction exceeding 1.5x TRVN's 36.13%. David Dodd would verify capital allocation.
0.91%
Diluted share reduction exceeding 1.5x TRVN's 36.13%. David Dodd would verify capital allocation.